AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tetratherix Ltd

6.750

+0.1201.81%

Volume:17.03K

Turnover:113.60K

Market Cap:357.27M

PE:-36.72

High:6.750

Open:6.630

Low:6.500

Close:6.630

52wk High:8.080

52wk Low:3.090

Shares:52.93M

Float Shares:16.15M

Volume Ratio:1.02

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.184

EPS(LYR):-0.184

ROE:-31.08%

ROA:-14.05%

PB:10.92

PE(LYR):-36.72

Loading ...

Overview Company News Filings

Australia's Tetratherix Rises After FDA Review Update on Tegenix Application

Tetratherix - FDA Requests Extra Detail on Chemical Characterisation and Product Labelling for Tegenix

THOMSON REUTERS

Tetratherix - Receives Substantive FDA Review Update for Tegenix 510(k) Submission

THOMSON REUTERS

Tetratherix - FDA Confirms Device Classification, Predicate Device, and Performance Data for Tegenix

THOMSON REUTERS

Tetratherix Completes First Preclinical Performance Study for Eye Surgery Device

MT Newswires Live

Tetratherix Begins Tetramatrix Product Revenue With First US Shipment

MT Newswires Live

Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise

MT Newswires Live

Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments

MT Newswires Live

Tetratherix Completes Share Purchase Plan

MT Newswires Live

Tetratherix Says Research Validation of Polymer Product Confirms Enabling of Direct Absorption into the Bloodstream

MT Newswires Live

BRIEF-Tetratherix Receives Firm Commitments For A$15 Million Placement At Issue Price Of A$6

Tetratherix Raises AU$15 Million Via Institutional Placement; Shares Tumble 6%

MT Newswires Live

Tetratherix - Receives Firm Commitments for a$15 Mln Placement at Issue Price of a$6

THOMSON REUTERS

Market Chatter: Tetratherix Seeks to Raise Around AU$15 Million Via Equity Raise, AFR Says

MT Newswires Live

BRIEF-Tetratherix Requests Trading Halt

A AU$90m Market Cap Boost Pleasing ToTetratherix Insiders

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/TTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","market":"AU","secType":"STK","nameCN":"Tetratherix Ltd","latestPrice":6.75,"timestamp":1791436320000,"preClose":6.63,"halted":0,"volume":17028,"delay":0,"changeRate":0.018099547511312233,"nameEN":"Tetratherix Ltd","floatShares":16151799,"shares":52929483,"eps":-0.1838,"marketStatus":"Closed","change":0.12,"latestTime":"10-08 16:12:00 AEDT","open":6.63,"high":6.75,"low":6.5,"amount":113597,"amplitude":0.037707,"askPrice":6.75,"askSize":4188,"bidPrice":6.3,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.1838,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":5,"adr":0,"listingDate":1751119200000,"exchange":"ASX","adjPreClose":6.63,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.023883,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TTX.AU","preClose":6.63,"auctionPrice":6.75,"auctionVolume":981,"auctionTime":1791436200788,"referencePrice":6.75,"referenceTime":1791438120442,"auction":3,"marketStatus":"盘后竞价","timestamp":1791436200788}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","floatShares":16151799,"roa":"-14.05%","roe":"-31.08%","lyrEps":-0.1838,"volumeRatio":1.023883,"shares":52929483,"dividePrice":0,"high":6.75,"amplitude":0.037707,"preClose":6.63,"low":6.5,"week52Low":3.09,"pbRate":"10.92","psRate":"92.52","week52High":8.08,"institutionHeld":0,"latestPrice":6.75,"committee":-0.472574,"eps":-0.1838,"divideRate":0,"volume":17028,"delay":0,"ttmEps":-0.1838,"open":6.63,"prevYearClose":3.28,"prevWeekClose":6.45,"prevMonthClose":6.3,"prevQuarterClose":6.3,"fiveDayClose":6.38,"twentyDayClose":6.92,"sixtyDayClose":6.81},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673087148","title":"Australia's Tetratherix Rises After FDA Review Update on Tegenix Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087148","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087148?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:15","pubTimestamp":1791242138,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Tetratherix rises after FDA review update on Tegenix application** Shares of TetratherixTTX.AXrise as much as 5% to A$6.70, their highest level since September 23** Medical technology","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673708245","title":"Tetratherix - FDA Requests Extra Detail on Chemical Characterisation and Product Labelling for Tegenix","url":"https://stock-news.laohu8.com/highlight/detail?id=2673708245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673708245?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:56","pubTimestamp":1791237414,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R179:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673452082","title":"Tetratherix - Receives Substantive FDA Review Update for Tegenix 510(k) Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2673452082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673452082?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:56","pubTimestamp":1791237414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R179:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673082454","title":"Tetratherix - FDA Confirms Device Classification, Predicate Device, and Performance Data for Tegenix","url":"https://stock-news.laohu8.com/highlight/detail?id=2673082454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673082454?lang=en_us&edition=fundamental","pubTime":"2026-10-06 05:56","pubTimestamp":1791237414,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R179:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667558679","title":"Tetratherix Completes First Preclinical Performance Study for Eye Surgery Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2667558679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667558679?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:25","pubTimestamp":1789525553,"startTime":"0","endTime":"0","summary":"Tetratherix  said it completed its first preclinical performance study for its ophthalmic viscosurgical device, Optimatrix, in cataract surgery with a recognized animal model, according to a Wednesday Australian bourse filing.Animals underwent a cataract operation in both eyes, on the same day and by the same surgeon. In one eye, Optimatrix was used and then left in place. In the other eye, a sham procedure was performed using a salt solution, which was removed at the end of the procedure.With Optimatrix, even with the product remaining inside the eye, intraocular eye pressure was back at pre-operative levels within six hours and did not rise again by 48 hours. The surgical device was developed from Tetramatrix's platform polymer.Two new patents were lodged covering the composition of matter and the use application for cataract surgery.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663618023","title":"Tetratherix Begins Tetramatrix Product Revenue With First US Shipment","url":"https://stock-news.laohu8.com/highlight/detail?id=2663618023","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663618023?lang=en_us&edition=fundamental","pubTime":"2026-08-31 08:50","pubTimestamp":1788137454,"startTime":"0","endTime":"0","summary":"Tetratherix  made its first commercial shipment of Tetramatrix polymer to the US under its Precision Medicine partnership with Superpower Health, adding product revenue to its existing $3 million annual license fee, according to a Monday filing with the Australian bourse.The shipment follows successful US export clearance, commercial-scale manufacturing, and the US Food and Drug Administration's assignment of a unique identifier to the company's STEPP polymer platform, per the filing.The company also said a peer-reviewed study on its PNPHO polymer for intranasal semaglutide delivery was accepted by the International Journal of Pharmaceutics, independently validating the technology and its potential for peptide drug delivery, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653733736","title":"Tetratherix Improves Cash Position With Inaugural Superpower License Fee, Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2653733736","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653733736?lang=en_us&edition=fundamental","pubTime":"2026-07-22 12:00","pubTimestamp":1784692834,"startTime":"0","endTime":"0","summary":"Tetratherix  received its first license fee revenue of $3 million in the June quarter as part of an exclusive research and development agreement with US consumer health group Superpower, according to a Wednesday filing with the Australian bourse.The fee revenue, combined with a net AU$14.7 million from a placement in May, left the company with a \"strong cash position\" of AU$34.4 million as of June 30, per the filing.The company closed the March quarter with AU$19.2 million of cash on hand, a previous filing showed.Tetratherix said it saw AU$19.3 million of cash inflows in the three months through June, bringing the total to AU$21.9 million for the full 2026 fiscal year.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645300206","title":"Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2645300206","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645300206?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:57","pubTimestamp":1782187060,"startTime":"0","endTime":"0","summary":"Tetratherix  said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OZR.AU","OZF.AU","IOZ.AU","BBOZ.AU","E200.AU","JYNT","GIVE.AU","ZYAU.AU","STW.AU","BK7067","IISV.AU","SLF.AU","BK4185","TTX.AU","VAP.AU","IMLC.AU","EIGA.AU","XJO.AU","DACE.AU","GEAR.AU","IIGF.AU","QRE.AU","XAO.AU","VAS.AU","BEAR.AU","QFN.AU","XKO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645145900","title":"Tetratherix Completes Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645145900","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645145900?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:33","pubTimestamp":1782088397,"startTime":"0","endTime":"0","summary":"Tetratherix  completed its share purchase plan, receiving applications totaling AU$639,644 at an issue price of AU$6 apiece, according to a Monday filing with the Australian bourse.Proceeds will be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and offer costs, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642454395","title":"Tetratherix Says Research Validation of Polymer Product Confirms Enabling of Direct Absorption into the Bloodstream","url":"https://stock-news.laohu8.com/highlight/detail?id=2642454395","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642454395?lang=en_us&edition=fundamental","pubTime":"2026-06-09 13:42","pubTimestamp":1780983779,"startTime":"0","endTime":"0","summary":"Tetratherix  said further research validation of the Tetramatrix platform polymer product confirmed it forms a protective, adhesive carrier on the nasal lining, guarding compounds from degradation and enabling direct absorption into the bloodstream, according to a Tuesday Australian bourse filing.The peer-reviewed study applied the product to insulin, confirming greater than 99% encapsulation, stability, protection from enzymatic degradation, and statistically superior compound delivery to the bloodstream and brain compared with unformulated insulin.Another study tested the product against bovine serum albumin and showed high encapsulation efficiency, stability over four weeks when refrigerated, zero cytotoxicity, greater deposition in the olfactory region, and a statistically significant increase in the tightening of nasal cell junctions.The studies were led by researchers at the Woolcock Institute of Medical Research, a Tetratherix research collaborator.Its shares rose 1% in recent t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638630095","title":"BRIEF-Tetratherix Receives Firm Commitments For A$15 Million Placement At Issue Price Of A$6","url":"https://stock-news.laohu8.com/highlight/detail?id=2638630095","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638630095?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:01","pubTimestamp":1779930104,"startTime":"0","endTime":"0","summary":"BRIEF-Tetratherix Receives Firm Commitments For A$15 Million Placement At Issue Price Of A$6May 28 (Reuters) - Tetratherix Ltd TTX.AX:RECEIVES FIRM COMMITMENTS FOR A$15 MILLION PLACEMENT AT ISSUE PRICE OF A$6Further company coverage: TTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN42416E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638963726","title":"Tetratherix Raises AU$15 Million Via Institutional Placement; Shares Tumble 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638963726","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638963726?lang=en_us&edition=fundamental","pubTime":"2026-05-28 08:25","pubTimestamp":1779927930,"startTime":"0","endTime":"0","summary":"Tetratherix  said it has received firm commitments from new and existing institutional investors to raise AU$15 million through a placement at AU$6 per share, representing a 2% discount to the 10-day volume-weighted average price of AU$6.12, according to a Thursday Australian bourse filing.The company said tranche 1 shares are anticipated to settle on June 3, while tranche 2 shares issued to directors are subject to shareholder approval at a general meeting.The company will also offer a share purchase plan  to existing eligible shareholders to raise a further AU$2 million, with proceeds from the placement and SPP to be used to fund production expansion, strategic partnerships, customer success, digitalization, working capital, and transaction costs.The company's shares tumbled 6% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638632580","title":"Tetratherix - Receives Firm Commitments for a$15 Mln Placement at Issue Price of a$6","url":"https://stock-news.laohu8.com/highlight/detail?id=2638632580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638632580?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:24","pubTimestamp":1779924290,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN42416E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638598634","title":"Market Chatter: Tetratherix Seeks to Raise Around AU$15 Million Via Equity Raise, AFR Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2638598634","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638598634?lang=en_us&edition=fundamental","pubTime":"2026-05-26 13:12","pubTimestamp":1779772353,"startTime":"0","endTime":"0","summary":"Tetratherix  is reportedly looking to raise around AU$15 million from an equity raising at AU$6 per share, and it has brought in Barrenjoey Capital Partners and Morgans, the Australian Financial Review  reported on Tuesday.The offering is said to be cornerstoned by a global healthcare investor, the report said.The firm requested a halt in trading of its shares from the open of trading on Tuesday in connection with a proposed material capital raising, according to a same-day Australian bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4215","EQR","BK4585","TTX.AU","BK4588","AFR.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638563526","title":"BRIEF-Tetratherix Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2638563526","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638563526?lang=en_us&edition=fundamental","pubTime":"2026-05-26 07:39","pubTimestamp":1779752344,"startTime":"0","endTime":"0","summary":"BRIEF-Tetratherix Requests Trading HaltMay 26 (Reuters) - Tetratherix Ltd TTX.AX:REQUESTS TRADING HALT FOR PROPOSED MATERIAL CAPITAL RAISINGFurther company coverage: TTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260525:nFWN4220EA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637393437","title":"A AU$90m Market Cap Boost Pleasing ToTetratherix Insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2637393437","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637393437?lang=en_us&edition=fundamental","pubTime":"2026-05-22 11:55","pubTimestamp":1779422149,"startTime":"0","endTime":"0","summary":"Insiders who bought Tetratherix Limited ( ASX:TTX ) stock in the last 12 months were richly rewarded last week. The...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ttx/tetratherix-shares/news/a-au90m-market-cap-boost-pleasing-totetratherix-insiders","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ttx/tetratherix-shares/news/a-au90m-market-cap-boost-pleasing-totetratherix-insiders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TTX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}